PMID- 19216775
OWN - NLM
STAT- MEDLINE
DCOM- 20090826
LR  - 20211020
IS  - 1756-9966 (Electronic)
IS  - 0392-9078 (Print)
IS  - 0392-9078 (Linking)
VI  - 28
IP  - 1
DP  - 2009 Feb 13
TI  - Comparison of cisplatin sensitivity and the 18F fluoro-2-deoxy 2 glucose uptake 
      with proliferation parameters and gene expression in squamous cell carcinoma cell 
      lines of the head and neck.
PG  - 17
LID - 10.1186/1756-9966-28-17 [doi]
AB  - BACKGROUND: The survival of patients with locally advanced head and neck cancer 
      is still poor, with 5-year survival rates of 24-35%. The identification of 
      prognostic and predictive markers at the molecular and cellular level could make 
      it possible to find new therapeutic targets and provide "taylor made" treatments. 
      Established cell lines of human squamous cell carcinoma (HNSCC) are valuable 
      models for identifying such markers.The aim of this study was to establish and 
      characterize a series of cell lines and to compare the cisplatin sensitivity and 
      18F fluoro-2 deoxy 2 glucose (18F-FDG) uptake of these cell lines with other 
      cellular characteristics, such as proliferation parameters and TP53 and CCND1 
      status. METHODS: Explant cultures of fresh tumour tissue were cultivated, and six 
      new permanent cell lines were established from 18 HNSCC cases. Successfully grown 
      cell lines were analysed regarding clinical parameters, histological grade, 
      karyotype, DNA ploidy, and index and S-phase fraction (Spf). The cell lines were 
      further characterized with regard to their uptake of 18F-FDG, their sensitivity 
      to cisplatin, as measured by a viability test (crystal violet), and their TP53 
      and CCND1 status, by fluorescence in situ hybridization (FISH), polymerase chain 
      reaction single-strand conformation polymorphism (PCR-SSCP) with DNA sequencing 
      and, for cyclin D1, by immunohistochemistry. RESULTS: Patients with tumours that 
      could be cultured in vitro had shorter disease-free periods and overall survival 
      time than those whose tumours did not grow in vitro, when analysed with the 
      Kaplan-Meier method and the log-rank test. Their tumours also showed more complex 
      karyotypes than tumours from which cell lines could not be established. No 
      correlation was found between TP53 or CCND1 status and 18F-FDG uptake or 
      cisplatin sensitivity. However, there was an inverse correlation between tumour 
      cell doubling time and 18F-FDG uptake. CONCLUSION: In vitro growth of HNSCC cells 
      seem to be an independent prognostic factor, with cell lines being more readily 
      established from aggressive tumours, a phenomenon more dependent on the molecular 
      genetic characteristics of the tumour cells than on tumour location or TNM 
      status.
FAU - Henriksson, Eva
AU  - Henriksson E
AD  - Department of Otorhinolaryngology, University Hospital Malmo, SE-205 02 Malmo, 
      Sweden. Eva.Henriksson@skane.se
FAU - Kjellen, Elisabeth
AU  - Kjellen E
FAU - Baldetorp, Bo
AU  - Baldetorp B
FAU - Bendahl, Par-Ola
AU  - Bendahl PO
FAU - Borg, Ake
AU  - Borg A
FAU - Brun, Eva
AU  - Brun E
FAU - Mertens, Fredrik
AU  - Mertens F
FAU - Ohlsson, Tomas
AU  - Ohlsson T
FAU - Rennstam, Karin
AU  - Rennstam K
FAU - Wennerberg, Johan
AU  - Wennerberg J
FAU - Wahlberg, Peter
AU  - Wahlberg P
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20090213
PL  - England
TA  - J Exp Clin Cancer Res
JT  - Journal of experimental & clinical cancer research : CR
JID - 8308647
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Radiopharmaceuticals)
RN  - 0Z5B2CJX4D (Fluorodeoxyglucose F18)
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
MH  - Antineoplastic Agents/pharmacology
MH  - Carcinoma, Squamous Cell/*drug therapy/genetics/*metabolism/pathology
MH  - Cell Line, Tumor
MH  - Chromosome Banding
MH  - Cisplatin/*pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Drug Screening Assays, Antitumor
MH  - Fluorodeoxyglucose F18/*pharmacokinetics
MH  - Gene Expression
MH  - Genes, p53
MH  - Head and Neck Neoplasms/*drug therapy/genetics/*metabolism/pathology
MH  - Humans
MH  - Mutation
MH  - Radiopharmaceuticals/pharmacokinetics
PMC - PMC2654548
EDAT- 2009/02/17 09:00
MHDA- 2009/08/27 09:00
PMCR- 2009/02/13
CRDT- 2009/02/17 09:00
PHST- 2008/08/27 00:00 [received]
PHST- 2009/02/13 00:00 [accepted]
PHST- 2009/02/17 09:00 [entrez]
PHST- 2009/02/17 09:00 [pubmed]
PHST- 2009/08/27 09:00 [medline]
PHST- 2009/02/13 00:00 [pmc-release]
AID - 1756-9966-28-17 [pii]
AID - 10.1186/1756-9966-28-17 [doi]
PST - epublish
SO  - J Exp Clin Cancer Res. 2009 Feb 13;28(1):17. doi: 10.1186/1756-9966-28-17.